US0758871091 - Common Stock
BECTON DICKINSON AND CO
NYSE:BDX (5/17/2024, 7:04:00 PM)
After market: 236.3 0 (0%)236.3
-0.32 (-0.14%)
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 73,000 full-time employees. The firm is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The firm's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The firm's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The firm's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
BECTON DICKINSON AND CO
One Becton Drive
Franklin Lakes NEW JERSEY 07417
P: 12018476800
CEO: Thomas E. Polen
Employees: 73000
Website: https://www.bd.com/
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration...
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX shares Outperform.
Unusual volume S&P500 stocks in Thursday's session
BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7%...
Here you can normally see the latest stock twits on BDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: